Literature DB >> 9626814

Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride.

D M Evans1, K Sloan-Stakleff, M Arvan, D P Guyton.   

Abstract

Amiloride is an inhibitor of urokinase plasminogen activator (uPA), an essential component of the plasminogen/plasmin enzyme system. Inhibition of uPA prevents the conversion of plasminogen to tumor cell surface bound plasmin which is required for initiation of the metastatic process. MATB rat mammary cancer cells were introduced into the jugular venous system of 80 Fisher 344 female rats. Amiloride at high and low dosages was administered in the drinking water at the time of, prior to or several days following the tumor cell inoculation and continued daily for 10 days post inoculation. Control rats were maintained on water alone. The middle lobe of the right lung was examined microscopically for numbers of metastases. Suppression of metastases was significant at high amiloride dosages in all groups, and at low dosage when administered prior to inoculation. We conclude that amiloride suppresses induced metastases of rat mammary cancer, the effect being dose- and time-dependent.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626814     DOI: 10.1023/a:1006517614491

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  22 in total

1.  Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade.

Authors:  P Mignatti; E Robbins; D B Rifkin
Journal:  Cell       Date:  1986-11-21       Impact factor: 41.582

Review 2.  Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness.

Authors:  F Blasi
Journal:  Bioessays       Date:  1993-02       Impact factor: 4.345

Review 3.  Factors regulating interaction between trophoblast and human endometrium.

Authors:  C Flamigni; C Bulletti; V Polli; P M Ciotti; R A Prefetto; A Galassi; E Di Cosmo
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

4.  The fibrinolytic system. A key to tumor metastasis?

Authors:  J M Malone; S L Wangensteen; W S Moore; K Keown
Journal:  Ann Surg       Date:  1979-09       Impact factor: 12.969

5.  Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor.

Authors:  D M Evans; P L Lin
Journal:  Am Surg       Date:  1995-08       Impact factor: 0.688

6.  Antibodies to plasminogen activator inhibit human tumor metastasis.

Authors:  L Ossowski; E Reich
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

7.  Plasminogen activators as markers of tumor colonization potential.

Authors:  R Ng; J A Kellen; A C Wong
Journal:  Invasion Metastasis       Date:  1983

8.  Prevention of metastasis by inhibition of the urokinase receptor.

Authors:  C W Crowley; R L Cohen; B K Lucas; G Liu; M A Shuman; A D Levinson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  Amiloride inhibits the growth of human colon cancer cells in vitro.

Authors:  J Y Koo; D Parekh; C M Townsend; R Saydjari; B M Evers; A Farre; J Ishizuka; J C Thompson
Journal:  Surg Oncol       Date:  1992-12       Impact factor: 3.279

10.  In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.

Authors:  L Ossowski
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

View more
  11 in total

1.  RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growth.

Authors:  Shakuntala Kondraganti; Christopher S Gondi; Ian McCutcheon; Dzung H Dinh; Meena Gujrati; Jasti S Rao; William C Olivero
Journal:  Int J Oncol       Date:  2006-06       Impact factor: 5.650

2.  Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth.

Authors:  Christopher S Gondi; Sajani S Lakka; Dzung H Dinh; William C Olivero; Meena Gujrati; Jasti S Rao
Journal:  Neuron Glia Biol       Date:  2004-05

3.  Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.

Authors:  Douglas M Evans; Kimberly D Sloan Stakleff
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  Amiloride and guggulsterone suppression of esophageal cancer cell growth in vitro and in nude mouse xenografts.

Authors:  Baoxiang Guan; Ashraful Hoque; Xiaochun Xu
Journal:  Front Biol (Beijing)       Date:  2014-02

5.  The epithelial sodium channel has a role in breast cancer cell proliferation.

Authors:  Adam W Ware; Joshua J Harris; Tania L Slatter; Heather E Cunliffe; Fiona J McDonald
Journal:  Breast Cancer Res Treat       Date:  2021-02-25       Impact factor: 4.872

6.  u-PA inhibitor amiloride suppresses peritoneal metastasis in gastric cancer.

Authors:  Youcheng Ding; Hui Zhang; Zhuqing Zhou; Mingan Zhong; Qiliang Chen; Xujing Wang; Zhenggang Zhu
Journal:  World J Surg Oncol       Date:  2012-12-12       Impact factor: 2.754

Review 7.  Synergy Between Low Dose Metronomic Chemotherapy and the pH-centered Approach Against Cancer.

Authors:  Tomas Koltai; Rosa A Cardone; Stephan J Reshkin
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

Review 8.  Cancer cell metabolism: implications for therapeutic targets.

Authors:  Miran Jang; Sung Soo Kim; Jinhwa Lee
Journal:  Exp Mol Med       Date:  2013-10-04       Impact factor: 8.718

Review 9.  A New and Integral Approach to the Etiopathogenesis and Treatment of Breast Cancer Based upon Its Hydrogen Ion Dynamics.

Authors:  Salvador Harguindey; Khalid Alfarouk; Julián Polo Orozco; Kevin Hardonniere; Daniel Stanciu; Stefano Fais; Jesús Devesa
Journal:  Int J Mol Sci       Date:  2020-02-07       Impact factor: 5.923

Review 10.  Towards an Integral Therapeutic Protocol for Breast Cancer Based upon the New H+-Centered Anticancer Paradigm of the Late Post-Warburg Era.

Authors:  Salvador Harguindey; Khalid Alfarouk; Julián Polo Orozco; Stefano Fais; Jesús Devesa
Journal:  Int J Mol Sci       Date:  2020-10-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.